contraction between the body of the left ventricle and the papillary muscles, which leads to mitral regurgitation, rapid decompression of the left ventricle, and concentric hypertrophy. The importance of outflow tract obstruction and the possible contribution of excessive catecholamines within the heart in producing an abnormally powerful and rapid contraction of the left ventricle are debated.

It is concluded that while lesions which produce eccentric hypertrophy do not usually involve the papillary muscles or cause subvalvar mitral regurgitation, disorders which cause obstruction to outflow and which are associated with concentric hypertrophy and with reduction in the size of the cavity in systole are often associated with papillary muscle disorder and thus with mitral regurgitation.

I should like particularly to acknowledge the debt I owe to Professor Robert Steiner, Mr. William Cleland, and Professor Hugh Bentall. Much of the work described was performed in the Unit of Clinical Cardiology by Dr. C. M. Oakley, Dr. K. A. Hallidie-Smith, and Dr. E. B. Raftery. I also acknowledge the important work of Dr. Arthur Hollman in our earlier studies.

REFERENCES

- Arvidsson, H. (1961). *Acta radiol. (Stockh.)*, **56**, 321.
 Björk, V. O., Hultquist, G., and Lodin, H. (1961). *J. thorac. cardiovasc. Surg.*, **41**, 659.
 Braunwald, E., Lambrew, C. T., Harrison, D. C., and Morrow, A. G. (1964). In *Cardiomyopathies*, Ciba Symposium, edited by G. E. W. Wolstenholme and M. O'Connor, p. 172. London.
 ——— Morrow, A. G., Cornell, W. P., Aygen, M. M., and Hilbish, T. F. (1960). *Amer. J. Med.*, **29**, 924.
 Brock, R. (1957). *Guy's Hosp. Rep.*, **106**, 221.
 Brockenbrough, E. C., Braunwald, E., and Morrow, A. G. (1961). *Circulation*, **23**, 189.
 Burch, G. E., De Pasquale, N. P., and Phillips, J. A. (1963). *Arch. intern. Med.*, **112**, 112.
 Cherian, G., Brockington, I. F., Shah, P. M., Oakley, C. M., and Goodwin, J. F. (1966). *Brit. med. J.*, **1**, 895.
 Cohen, J., Effat, H., Goodwin, J. F., Oakley, C. M., and Steiner, R. E. (1964). *Brit. Heart J.*, **26**, 16.
 Criley, J. M., Lewis, K. B., White, R. I., jun., and Ross, R. S. (1965). *Circulation*, **32**, 881.
 Daoud, G., Gallaher, M. E., and Kaplan, S. (1961). *Amer. J. Cardiol.*, **7**, 860.
 Everson Pearce, A. G. (1964). In *Cardiomyopathies*, Ciba Symposium, edited by G. E. W. Wolstenholme and M. O'Connor, p. 132. London.
 Goodwin, J. F. (1964). *Brit. med. J.*, **1**, 1527, 1595.
 ——— Hollman, A., Cleland, W. P., and Teare, D. (1960). *Brit. Heart J.*, **22**, 403.
 ——— Shah, P. M., Oakley, C. M., Cohen, J., Yipintsoi, T., and Pocock, W. (1964). In *Cardiomyopathies*, Ciba Symposium, edited by G. E. W. Wolstenholme and M. O'Connor, p. 189. London.
 Grant, C. (1967). To be published.
 ——— Greene, D. G., and Bunnell, I. L. (1965). *Amer. J. Med.*, **39**, 895.
 Hallidie-Smith, K. A., Oakley, C. M., and Goodwin, J. F. (1967). Communication to British Cardiac Society. To be published.
 Lewis, C. M. (1966). Communication to Biennial Congress of Southern African Cardiac Society, Stellenbosch.
 Linzbach, A. J. (1960). *Amer. J. Cardiol.*, **5**, 370.
 Moller, J. H., Nakib, A., and Edwards, J. E. (1966). *Circulation*, **34**, 87.
 Morrow, A. G., and Braunwald, E. (1959). *Ibid.*, **20**, 181.
 ——— Vasko, J. S., Henney, R. P., and Brawley, R. K. (1965). *Amer. J. Cardiol.*, **16**, 540.
 Nadas, A. S., Thilenius, O. G., LaFarge, C. G., and Hauck, A. J. (1964). *Circulation*, **29**, 862.
 Nellen, M., Schrire, V., and Vogelpoel, L. (1959). *S. Afr. med. J.*, **33**, 91.
 Neufeld, H. N., Ongley, P. A., and Edwards, J. E. (1960). *Brit. Heart J.*, **22**, 686.
 Oakley, C. M., and Hallidie-Smith, K. A. (1967). *Ibid.*, **29**, 367.
 ——— Raftery, E. B., Goodwin, J. F., and Steiner, R. E. (1967). To be published.
 Paré, J. A. P., Fraser, R. G., Pirozynski, W. J., Shanks, J. A., and Stubington, D. (1961). *Amer. J. Med.*, **31**, 37.
 Raftery, E. B. (1965). *Brit. Heart J.*, **27**, 286.
 ——— Oakley, C. M., and Goodwin, J. F. (1966). *Lancet*, **2**, 360.
 Ross, J., jun., Braunwald, E., Gault, J. H., Mason, D. T., and Morrow, A. G. (1966). *Circulation*, **34**, 558.
 Rushmer, R. F. (1961). *Cardiovascular Dynamics*, 2nd ed. London.
 Schmincke, A. (1907). *Dtsch. med. Wschr.*, **33**, 2082.
 Shah, P. M., Amarasingham, R., and Oakley, C. M. (1965a). *Brit. Heart J.*, **27**, 83.
 ——— Yipintsoi, T., Amarasingham, R., and Oakley, C. M. (1965b). *Amer. J. Cardiol.*, **15**, 793.
 Tandler, J. (1926). *Lehrbuch der Systematischen Anatomie*, 2nd ed. Leipzig.
 Teare, D. (1958). *Brit. Heart J.*, **20**, 1.
 Vogel, J. H. K., and Blount, S. G., jun. (1965). *Amer. J. Cardiol.*, **15**, 782.
 Walmsley, R., and Watson, H. (1966). *Brit. Heart J.*, **28**, 435.
 Wile, E. D., Chrysohou, A., and Bigelow, W. G. (1963). *Amer. J. Cardiol.*, **11**, 572.

Effect of Prostaglandin E₁ on Platelet Behaviour in Vitro and in Vivo

P. R. EMMONS,* B.A., D.PHIL., M.D.; J. R. HAMPTON,* M.A., D.PHIL., B.M., M.R.C.P.
 M. J. G. HARRISON,* M.A., B.M., M.R.C.P.; A. J. HONOUR,* M.A., D.PHIL.
 J. R. A. MITCHELL,* M.A., M.D., B.SC., D.PHIL., M.R.C.P.

Brit. med. J., 1967, **2**, 468–472

Prostaglandins were first isolated by Goldblatt (1933) and von Euler (1934) from human seminal plasma and sheep seminal vesicles, and have since been found in other tissues (Bergström, 1965). One member of the group, prostaglandin E₁ (PGE₁), was shown to have very powerful vasodepressor activity, and in view of the close parallelism between the vasoactivity of compounds and their ability to affect platelet behaviour (Born *et al.*, 1965; Hampton *et al.*, 1967) it seemed likely that PGE₁ would be found to inhibit platelet aggregation.

Kloeze (1966) showed that in very low concentration PGE₁ could inhibit adenosine diphosphate (A.D.P.)-induced aggregation of rat, pig, and human platelets, and A.D.P.-induced glass adhesiveness of rat platelets. We report here some further effects of PGE₁ on aggregation induced by other agents, on glass adhesiveness in a whole-blood system, on the electrokinetic changes which A.D.P. and noradrenaline induce in platelets, and on the production of platelet thrombi in injured arteries in the rabbit.

Methods

Prostaglandin Solutions.—PGE₁ was dissolved in 96% ethanol to produce a stock solution of 100 µg./ml., which was stored at –20° C. The dilutions required for the various

experiments were made by adding aliquots of the stock solution to normal saline.

Blood samples were taken into siliconized glass syringes from the antecubital veins of healthy volunteers or from hospital patients without acute illnesses or vascular disease. Then 9-ml. aliquots were transferred to siliconized centrifuge tubes containing 1 ml. of 3.8% trisodium citrate and gently mixed.

Platelet-to-glass adhesiveness in whole blood was measured by a modification of the Payling Wright (1941) technique (Emmons *et al.*, 1965a), and to assess the effect of PGE₁ 0.1 ml. of normal saline or of PGE₁ in normal saline was added to 1.9 ml. of whole blood. Duplicate platelet counts were performed by the method of Brecher and Cronkite (1950) before and after rotating the 2-ml. samples in conical glass flasks for 40 minutes, and the fall in platelet count during rotation of the samples was expressed as a percentage of the initial count.

Platelet aggregation was studied by a modification of the Born (1962) optical density technique (Emmons and Mitchell, 1965). The optical density of platelet-rich plasma falls as aggregates form and rises again if they disperse. The fall

* Department of the Regius Professor of Medicine, Radcliffe Infirmary, Oxford.

in optical density at various stages of aggregation is expressed as a percentage of that produced by high-speed centrifugation. Platelet-rich citrated plasma (P.R.C.P.) was prepared by centrifuging whole blood at 200 g. for 10 minutes. 0.1 ml. of prostaglandin solution, of adenosine (Sigma), or of normal saline was added to 0.4 ml. of the P.R.C.P. before the addition of 0.1 ml. of aggregating agent. All experiments were carried out at 25° C. on P.R.C.P. less than one hour old.

The clumping agents used and their final concentrations were: A.D.P. 0.5 µg./ml. and 1.5 µg./ml.; noradrenaline 1.5 µg./ml.; 5-hydroxytryptamine (5-HT) 1.5 µg./ml.; adenosine triphosphate (A.T.P.) 15 µg./ml. (all from Sigma); connective tissue extract prepared by the method of Zucker and Borrelli (1962); and thrombin 0.2 unit/ml.

Platelet Electrophoretic Mobility.—P.R.C.P. was prepared, diluted with nine parts of platelet-poor plasma (P.P.P.), and the mixture brought into contact with non-siliconized glass as described previously (Hampton and Mitchell, 1966a, 1966b). Platelet electrophoretic mobility was measured at 25° C. in the horizontal capillary apparatus designed by Bangham *et al.* (1958), using a potential gradient of 2.66 V/cm. Mobilities were expressed as µ/sec./V/cm. PGE₁ solution was incubated with the P.R.C.P./P.P.P. mixture for 10 minutes at 25° C.; control tubes containing saline were also set up and handled in parallel. A.D.P. or noradrenaline dissolved in normal saline was then added to the mixture to give a final concentration of 0.05 µg./ml. (which in healthy subjects causes the maximal increase in mobility) and 0.5 µg./ml. (which causes a significant decrease in mobility).

Platelet Behaviour in Vivo.—Male grey chinchilla rabbits were anaesthetized with intraperitoneal urethane, and the cerebral cortical arteries were exposed (Honour and Ross Russell, 1962). Two types of arterial injury were inflicted with needle-pointed forceps as described by Honour and Mitchell (1964): (a) *minor injuries* which do not produce white masses of platelets within the lumen of the vessel spontaneously but do so when aggregating agents are applied to the site of injury, and (b) *major injuries* which breach the vessel wall, cause transient external bleeding, and then go on to form

occluding intraluminal platelet masses (white bodies) which embolize and re-form over a period of several hours.

PGE₁ was either applied topically to the injured vessels from a pipette delivering 1 ml. in one minute or injected intravenously through an indwelling catheter in the jugular vein.

Results

Glass Adhesiveness

PGE₁ 2.5 µg./ml. inhibited platelet adhesiveness in each of 10 experiments (Table I) and the mean adhesiveness was reduced from 48.6±4.0% to 20±3.4% (*p*<0.001). There was considerable patient-to-patient variation in this reduction of adhesiveness; with lower concentration of PGE₁ even more variable results were obtained, and in some patients adhesiveness was significantly reduced in the presence of as little as 0.01 µg. of PGE₁ per ml.

Platelet Aggregation

PGE₁ inhibited A.D.P. and noradrenaline induced aggregation. The degree of inhibition was proportional to the concentration of inhibitor over a range of 0.001 to 1 µg./ml. (Fig. 1). As in the adhesiveness studies, the effectiveness of PGE₁ varied considerably from subject to subject; in a group of six individuals PGE₁ 1 µg./ml. reduced the mean maximum percentage change in optical density produced by A.D.P. 0.5 µg./ml. from 66 to 17% and by noradrenaline 1.5 µg./ml. from 66 to 8%. The inhibitory effect was enhanced by pre-incubating the prostaglandin with P.R.C.P. for 10 minutes before the addition of A.D.P., but incubation for longer periods of up to one hour had no further effect. When PGE₁ was added after aggregation had already occurred (Fig. 2) the aggregates dispersed rapidly.

The inhibitory activity of PGE₁ was compared with that of adenosine. In five experiments the mean maximum fall in optical density produced by A.D.P. 0.5 µg./ml. was 68% in the control tubes, 50% in the presence of adenosine 1×10⁻³ M, and 17% with PGE₁ 2.8×10⁻⁶ M (1 µg./ml). PGE₁ is therefore a more powerful inhibitor of ADP-induced aggregation than adenosine.

PGE₁ (1 µg./ml.) also inhibited the aggregation produced by A.T.P., 5-HT, thrombin, and connective-tissue extract (Table II). It had no effect on the recalcification time of whole blood and P.R.C.P. or on kaolin cephalin clotting times. No morphological abnormalities were seen under the phase contrast

TABLE I.—Platelet to Glass Adhesiveness With and Without PGE₁

	% Fall in Platelet Count after 40 Minutes* Rotation										Mean	S.E.
	33	39	65	36	77	53	44	50	45	44		
Saline control	33	39	65	36	77	53	44	50	45	44	48.6	±4.05
PGE ₁ 2.5 µg./ml.	16	21	21	14	24	24	0	40	8	32	20.0	±3.42

FIG. 1.—Percentage change in optical density produced by A.D.P. 0.5 µg./ml. in presence of various concentrations of PGE₁. N/S=normal saline control.

FIG. 2.—Effect of adding PGE₁ (final concentration 1 µg./ml.) and normal saline (N/S) two minutes after aggregation had been initiated by A.D.P. 0.5 µg./ml.

microscope of platelets from P.R.C.P. to which prostaglandin had been added.

TABLE II.—Effect of PGE₁ on Platelet Aggregation *in vitro*

Clumping Agent	Maximum % Change in Optical Density	
	Saline Control	PGE ₁ 1 µg./ml.
A.T.P. 15 µg./ml.	24	2
5-HT 1.5 µg./ml.	12	4
Connective-tissue extract	83	16
Thrombin 0.2 unit/ml.	25	0

Platelet Electrophoretic Mobility

(a) *Post-contact Mobility*.—PGE₁ in concentrations up to 1 µg./ml. had no effect on post-contact mobility.

(b) *Effect of A.D.P.*—Fig. 3 shows the effect of PGE₁ on the changes in platelet mobility induced by 0.05 and 0.5 µg. per ml. of A.D.P. The increasing and decreasing phases of the mobility change appear to have different sensitivities to PGE₁ in that 0.001 µg./per ml. of PGE₁ completely inhibited the decrease in mobility produced by 0.5 µg. of A.D.P. per ml. but had no effect on the increased mobility produced by 0.05 µg./ml. PGE₁ was also able to reverse the effect of A.D.P.: nine minutes after exposing the plasma mixture to 0.05 µg. of A.D.P. per ml. PGE₁ was added to give a final concentration of 1 µg./ml., normal saline being added to a control tube. The platelet mobility was measured as soon as possible, and in the control tube it had increased by 7% from its starting post-contact value, but in the tube to which PGE₁ had been added the increase in mobility was only 3%. Ten minutes later there was still a 4% increase in mobility in the control sample, but in the tube containing PGE₁ platelet mobility had returned to its initial post-contact value. The effect of added calcium on the action of PGE₁ was studied in the presence of heparin 2 u./ml., which

FIG. 3.—Platelet electrophoretic mobility changes induced by A.D.P. in presence of various concentrations of PGE₁. Upper section shows that 1 µg./ml. prevents the increase in mobility produced by A.D.P. 0.05 µg./ml., while the lower section shows that 0.001 µg./ml. can prevent the decrease in mobility produced by A.D.P. 0.5 µg./ml. Mobility values are expressed as a percentage of the basal, post-contact mobility.

itself was shown to have no influence on the platelet response to A.D.P. or on the effects of PGE₁. It was found that the addition of calcium chloride to give a theoretical increase in Ca⁺⁺ concentration of 25 mM completely abolished the effect of 0.001 µg. of PGE₁ per ml. on platelets challenged with 0.5 µg. of A.D.P. per ml.

(c) *Effect of PGE₁ on the Response to Noradrenaline*.—PGE₁ inhibited the changes in mobility induced by noradrenaline in the same way as those induced by A.D.P.: the decreasing phase of the response was more sensitive to PGE₁ than was the increasing phase. However, both phases of the mobility response to noradrenaline were 10 times less sensitive to PGE₁ than were the mobility responses to A.D.P.: 0.01 µg. PGE₁ per ml. had no effect on the changes induced by 0.05 µg. of noradrenaline per ml., and 0.001 µg. of PGE₁ per ml. had no effect on those induced by 0.5 µg./ml.

In-vivo Studies

(a) *The Topical Application of PGE₁ to minor injury sites* and to uninjured cerebral cortical arteries in concentrations of 2–40 µg./ml. did not produce platelet thrombi. Major injuries were then inflicted, and in each case white bodies began to form at the injury sites, embolizing every two to five minutes. PGE₁ 2–10 µg./ml. was then dripped on to the cortex, 1 ml. being applied in one minute. No effect was observed with 2 µg./ml., but with 5 and 10 µg./ml. white-body formation stopped during the application and did not restart for 5 to 10 minutes. The sites then became spontaneously active, forming white masses which embolized.

(b) *Intravenous Injection of PGE₁ After Injury*.—Major injuries were inflicted in a series of rabbit preparations, and, after they had produced large regularly embolizing platelet masses for at least 20 minutes, PGE₁ in 5 ml. of saline was given over the course of one minute into the jugular vein cannula. Table III summarizes the results and shows that in our preparations 5 µg. was ineffective, that 10 µg. was a marginally effective dose which affected white bodies only while the injection was proceeding, and that 25 µg. or more would inhibit white-body formation. In some of the preparations we observed that a site which had become completely quiescent after intravenous PGE₁ might begin to form tiny translucent white bodies some 20 to 40 minutes after the PGE₁. This activity would last for 5 to 10 minutes, when the site would again become inactive, remaining so throughout a further two-hour period of observation. We have also seen this pattern of behaviour in rabbits given adenosine and dipyridamole; it may represent a build-up in the circulation of a new population of platelets which have not as yet been exposed to the inhibitors, but its precise significance is not clear.

(c) *Intravenous Injection of PGE₁ Before Injury*.—In the rabbits which had received PGE₁ intravenously new major injuries were inflicted 30 to 40 minutes later. These produced small translucent emboli for a very short period (8 minutes with the 1,000-µg. dose; 20 minutes with 100 µg. and 10 minutes with 50 µg.) and then became inactive. Injuries inflicted 60 to 80 minutes after the PGE₁ produced larger and more dense emboli, but these were also short-lived in the animals given the larger doses (15 minutes with 1,000 µg. and 12 minutes

TABLE III.—Effect of Intravenous PGE₁ on White Body Formation in Injured Cerebral Arteries in the Rabbit

Dose		Effect
µg.	µg./kg.	
1,000	312	White-body production stopped within 1 minute of injection
100	34.5	
50	15.1	
25	9.3	White body washed away during injection. Then phasic production of tiny masses for 18 minutes, when site became inactive
10	4.1	White body washed away during injection. Phasic activity for 8 minutes, then became inactive
5	1.9	White body did not grow during injection. Thereafter, white masses produced in normal way
		No effect

with 100 µg.). In the animals given 50 and 25 µg. these late injuries showed the same response as in a normal animal, and formed dense white masses for as long as the observation was continued.

(d) *Intravenous Infusion of PGE₁*.—Two rabbits with active white-body-producing major injuries were studied. The first animal was given PGE₁ in normal saline via a jugular vein cannula, the drip-rate being adjusted so as to provide 0.2, 0.4, 0.8, and 1.6 µg./kg./min., each rate being maintained for 15 minutes. At the lowest infusion rate white-body formation continued unabated, but at 0.4 and 0.8 µg./kg./min. the white bodies forming at the site washed away in showers of tiny fragments. The residual mass at the site continually changed its shape and size, but was unable to grow across the lumen and did not give rise to discrete emboli. When 1.6 µg./kg./min. was infused the residual mass became progressively smaller and after 13 minutes the site became inactive. In the second animal the initial PGE₁ infusion was at a rate of 0.8 µg./kg./min. for 15 minutes, and the white mass at the injury site began to wash away as fast as it formed, showers of minute fragments swirling away from its periphery. During a 15-minute period at 1.6 µg./kg./min. the mass washed away more rapidly than it formed and became very small. Seven minutes after increasing the infusion rate to 3.2 µg./kg./min. the site became inactive. When the 15-minute infusion period at this rate was completed normal saline was substituted and the site immediately became active again, remaining so for 23 minutes. There was then a further 50-minute period of inactivity, after which white bodies formed until the animal was killed. As the prostaglandins are inactivated in the lungs (Bergström and Samuelsson, 1965) intra-arterial infusions may prove to be even more active in modifying white-body formation, and we are now examining the effect of intracarotid PGE₁.

Discussion

Kloeze (1966) showed that PGE₁ was a powerful inhibitor of A.D.P.-induced platelet aggregation in human, rat, and pig plasma, but found it to be without effect on platelet-to-glass adhesiveness in a platelet-rich plasma system to which A.D.P. had not been added. We have confirmed the effect of PGE₁ on A.D.P.-induced aggregation in man and have shown that it inhibits aggregation by other agents. We have also found that it inhibits platelet-to-glass adhesiveness when tested in a whole-blood system, that it modifies the electrokinetic response of platelets to A.D.P. and to noradrenaline, and that it inhibits the formation of platelet masses in injured rabbit cerebral cortical arteries.

In some of its effects on aggregation and adhesiveness PGE₁ resembles other vasoactive compounds (Hampton *et al.*, 1967), but there are some significant differences. First, PGE₁ is active at much lower concentrations than any other agent so far tested, and, second, like adenosine but unlike the other vasodilators, pre-incubation for 10 minutes enhances the inhibitory effect of PGE₁ on aggregation. PGE₁ also resembles adenosine in that it reduces the initial rate of aggregation and the maximum degree of aggregation attained, while other vasodilators which we have tested have little effect on these early phases of aggregation but markedly enhance disaggregation. The way in which adenosine itself acts is not known; it was thought to act as a competitive inhibitor of A.D.P. (Born and Cross, 1963), but the 10-minute lag before maximal inhibition, and the lack of inhibitory effect in species such as the cat and rat which nevertheless respond to A.D.P., suggest that we must seek an alternative explanation of its action.

In its ability to inhibit the electrokinetic response of platelets to A.D.P. and noradrenaline, PGE₁ also resembles other vasoactive agents. However, PGE₁ proved capable of influencing the platelet charge characteristics at much lower concentrations than other known inhibitors, and also proved to be more active against A.D.P. than noradrenaline. We found that the addition of Ca⁺⁺ ions counteracted the inhibitory

effects of PGE₁ and that PGE₁ was more active against the decrease in mobility produced by higher concentrations of A.D.P. and noradrenaline than against the increase in mobility produced by lower concentrations. This closely parallels the E.D.T.A. sensitivity and calcium requirement of the two phases of the mobility change, the decrease in mobility being more calcium-demanding. It seems possible that the action of PGE₁ on platelets may be mediated by alterations in their Ca⁺⁺ transport mechanism. We have already drawn attention to the structural and functional similarities between arterial smooth-muscle cells and platelets (both have a contractile protein with Ca⁺⁺-dependent A.T.P.-ase activity, and both show a common sensitivity to vasoactive agents). It is of interest that Coceani and Wolfe (1966) have suggested that the action of the prostaglandins in initiating contraction in the smooth muscle of the rat stomach is mediated by the facilitation of calcium influx or the release of bound calcium.

The mechanism of action of PGE₁ in the in-vivo preparation is also unknown. Other vasodilators are capable of inhibiting white-body formation, but there is no direct relation between their activity on thrombus formation in vivo and their ability to inhibit platelet aggregation in vitro. This lack of correlation and the activity of many of the compounds when applied locally suggests that some of them are acting on the injured artery wall cells rather than on the circulating platelets. For example, dipyrindamole has little effect on platelet aggregation in vitro but has a pronounced inhibitory effect on white-body formation when given intravenously or when applied locally (Emmons *et al.*, 1965b). In contrast, PGE₁ is a powerful inhibitor of in-vitro platelet behaviour, and in the rabbit is more active intravenously than when applied topically. It is likely, therefore, that it acts by an effect on the circulating platelets, and it is of interest that in the animals given PGE₁ there was no evidence of defective haemostatic plug formation.

The physiological role of prostaglandins is unknown. They are thought to be biosynthesized from arachidonic acid and homo-γ-linolenic acid, both of which have essential fatty acid activity. Early reports that linolenic acid itself could inhibit platelet adhesiveness (Owren *et al.*, 1964) could not later be confirmed (Borchgrevink *et al.*, 1965, 1966). There is no evidence that the essential fatty acids themselves have any of the properties which we have shown PGE₁ to possess, nor does it seem likely that the linolenic acid tested by Owren *et al.* (1964) contained prostaglandins.

It is not known whether any of the aspects of platelet behaviour which we have investigated are relevant to the pathogenesis of thrombotic arterial disease, but the ability of a biological material such as PGE₁ to exert profound effects on the blood platelets both in vitro and in vivo at such low concentrations makes it imperative to study its activities in greater detail.

Summary

Prostaglandin E₁ (PGE₁) is a powerful inhibitor of platelet-to-glass adhesiveness in a whole-blood system and of in-vitro platelet aggregation induced by A.D.P., noradrenaline, A.T.P., 5-HT, and connective-tissue extract. PGE₁ also inhibits the changes in platelet electrophoretic mobility produced by A.D.P. and by noradrenaline.

PGE₁ is active in vivo, for topical applications and intravenous injections or infusions suppress platelet thrombus formation in injured rabbit-brain arteries.

PGE₁ is found in many organs, and as it is capable of modifying platelet behaviour in vitro and in vivo in very low concentrations its role in the natural history and treatment of arterial thrombosis merits further study.

We are indebted to Dr. J. E. Pike, of the Department of Chemistry, Upjohn Company, Kalamazoo, Michigan, and to Dr. D. A. van Dorp, of Unilever Research Laboratories, Vlaardingen, Holland, for supplies of PGE₁ and for information about its

chemical properties. During the period of this study one of us (P.R.E.) was in receipt of a grant from the Medical Research Council.

Reprint requests to Dr. J. R. Hampton, Department of the Regius Professor of Medicine, Radcliffe Infirmary, Oxford.

REFERENCES

- Bangham, A. D., Flemons, R., Heard, D. H., and Seaman, G. V. F. (1958). *Nature (Lond.)*, 182, 642.
 Bergström, S. (1965). *J. Amer. Oil Chem. Soc.*, 42, 608.
 — and Samuelsson, B. (1965). *Ann. Rev. Biochem.*, 34, 101.
 Borchgrevink, C. F., Berg, K. J., Skaga, E., Skjeggstad, Ø. (1966). *Lancet*, 2, 187.
 — Stormorken, H. (1965). *Ibid.*, 2, 980.
 Born, G. V. R. (1962). *J. Physiol. (Lond.)*, 162, 67F.
 — and Cross, M. J. (1963). *Ibid.*, 168, 178.
 — Haslam, R. J., Goldman, M., and Lowe, R. D. (1965). *Nature (Lond.)*, 205, 678.
 Brecher, G., and Cronkite, E. P. (1950). *J. appl. Physiol.*, 3, 365.
 Cocceani, F., and Wolfe, L. S. (1966). *Canad. J. Physiol. Pharmacol.*, 44, 933.
 Emmons, P. R., Harrison, M. J. G., Honour, A. J., and Mitchell, J. R. A. (1965a). *Lancet*, 2, 603.
 — (1965b). *Nature (Lond.)*, 208, 255.
 — and Mitchell, J. R. A. (1965). *Lancet*, 1, 71.
 Goldblatt, M. W. (1933). *Chem. Ind.*, 52, 1056.
 Hampton, J. R., Harrison, M. J. G., Honour, A. J., and Mitchell, J. R. A. (1967). *Cardiovasc. Res.*, 1, 101.
 — and Mitchell, J. R. A. (1966a). *Nature (Lond.)*, 209, 470.
 — (1966b). *Brit. med. J.*, 1, 1074.
 Honour, A. J., and Mitchell, J. R. A. (1964). *Brit. J. exp. Path.*, 45, 75.
 — and Ross Russell, R. W. (1962). *Ibid.*, 43, 350.
 Kloeze, J. (1966). In *Proceedings of Nobel Symposium II, Stockholm*, 1966.
 Owren, P. A., Hellem, A. J., and Ødegaard, A. (1964). *Lancet*, 2, 975.
 von Euler, U. S. (1934). *Arch. exp. Path. Pharmacol.*, 175, 78.
 Wright, H. P. (1941). *J. Path. Bact.*, 53, 255.
 Zucker, M. B., and Borrelli, J. (1962). *Proc. Soc. exp. Biol. (N.Y.)*, 109, 779.

Vi Reaction in Hong Kong

C. R. FORREST,* M.D., M.R.C.P.GLASG.; R. NANETTE MATTHEWS,† D.C.H., M.R.C.P.
 M. J. ROBERTSON,‡ M.R.C.S., L.R.C.P., D.T.M.&H., DIP.BACT.; W. P. HANLEY,† M.A., L.R.C.P.&S.ED., D.P.H.

Brit. med. J., 1967, 2, 472-475

After 30 years the value of the Vi reaction remains controversial (Public Health Laboratory Service Working Party, 1961; Bokkenheuser and Richardson, 1964), and several factual points in connexion with the test are still in doubt. As typhoid fever is endemic in Hong Kong, it was decided to conduct an investigation into the use of the Vi reaction in the diagnosis and epidemiology of typhoid under the rather unusual conditions pertaining in the colony.

Before any work could be done on the place of the Vi reaction in the detection of typhoid carriers it was essential to ascertain the normal range in the general population.

In the study of the acute phase of typhoid an attempt was made to establish whether the Vi reaction could be an aid to the serological diagnosis of the disease, special emphasis being given to the possibility of forecasting clinical relapse or the development of the carrier state. The records were also examined for correlation between Vi titres and the following: age, severity of disease, Widal reaction, and treatment.

Method and Materials

Blood was collected for Vi examination from three groups of subjects: group 1, 100 orthopaedic patients and prisoners with negative histories for typhoid and T.A.B. vaccination; group 2, 75 patients with culturally proved typhoid on whom Vi examinations were carried out at weekly intervals during their stay in hospital, and then, so far as was possible, at three-monthly intervals up to 12 months; and group 3, 17 proved typhoid carriers.

Serological Examination

The Vi antibody test was carried out with a suspension prepared from the Colindale Vi suspension (Colindale Public Health Laboratory, London) and the standard Vi sera from Colindale as the reference sera. The prepared Vi antigen suspension was tested at regular intervals with the titrated standard sera and in conjunction with the sera under test. The titre of the test sera was taken as the reciprocal of that dilution of the sera giving the same degree of agglutination as that of the standard sera at a dilution of 1,600 set up at the same time.

The test itself was performed by adding 0.3 ml. of the antigen suspension to 0.3 ml. of the test sera diluted in twofold steps from $\frac{1}{2}$ to $\frac{1}{64}$, giving final reciprocal serum concentration

from 4 to 128, further doubling dilution being set up later if necessary. Both test and controls were incubated for two hours at 37° C. and then overnight in the refrigerator.

In reading the test the three standard diagnostic criteria were used to assess the degree of agglutination: the clearing of the supernatant, the pattern of the deposit, and the resultant granularity after agitating the tube.

Results

All Vi estimations were carried out by one of us (M. J. R.).

Normal Levels

Sera were obtained from 100 subjects representative of the main economic strata in Hong Kong, comprising orthopaedic patients and prisoners, none of whom gave a history of enteric-like infection or of T.A.B. immunization. The results of this sample are shown in Table I, which also gives the titres for those in the group who were under the age of 20.

The upper limit of normal was chosen as 32. This leaves 4% of the population as positive reactors. (At the British level of 5 as positive the Metropolitan Water Board found 3.2% positive reactors (P.H.L.S.W.P., 1961).)

TABLE I

Vi Titre:	Neg.	4	8	16	32	64	
Total No. of subjects	7	16	22	24	27	4	100
No. under 20	—	4	1	3	3	1	12

Acute Disease

The patients consisted of 75 unselected consecutive cases admitted to a Government hospital with typhoid fever. Before a case was accepted into the series it was necessary for *Salmonella typhi* to have been recovered from the blood or faeces. Apart from the exclusion of treated patients transferred late in the disease from other hospitals there was no selection. The sex incidence was equal, being 38 males and 37 females.

* Senior Medical and Health Officer, Medical and Health Department, Hong Kong.

† Medical and Health Officer, Medical and Health Department, Hong Kong.

‡ Pathologist, Medical and Health Department, Hong Kong.